AMAG Pharmaceuticals — Q1 2013 Earnings Presentation
24 slides from AMAG Pharmaceuticals's earnings presentation, Apr 23, 2013
Slide 1: AMAG Pharmaceuticals 1Q13 Financial Results
AMAG PHARMACEUTICALS 1Q13 Financial Results April 23, 2013
Slide 2: Forward Looking Statements
FORWARD LOOKING STATEMENTS 2 This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other federal securities laws. Any statements contained herein which do not describe historical facts, including but not limited to: (i) o
Slide 3: Agenda
AGENDA Topic Speaker Opening Remarks Bill Heiden, CEO Financial Highlights & Outlook Frank Thomas, COO Commercial Progress Greg Madison, CCO Expansion Opportunities and Closing Remarks Bill Heiden, CEO 3
Slide 4: First Quarter 2013 Highlights
FIRST QUARTER 2013 HIGHLIGHTS Strong financial performance 16% increase in total revenue vs. 1Q12 19% increase in U.S. Feraheme net sales driven by volume and net revenue per gram growth 24% decrease in operating expenses vs. 1Q12 Record non-dialysis provider demand – 29,500 grams 11% increase, E.I.
Slide 5: Financial Overview
FINANCIAL OVERVIEW Frank Thomas, Chief Operating Officer
Slide 6: Feraheme – On a Solid Growth Trajectory
FERAHEME – ON A SOLID GROWTH TRAJECTORY 6 *Excludes reduction of reserves for product returns and Medicaid in 2012 (in millions) +14% volume growth +5% price growth vs. 1Q2012 +17% volume growth -5% price decline vs. 2011
Slide 7: Improved Net Revenue per Gram
IMPROVED NET REVENUE PER GRAM Realizing benefit of price increases taken in 2012 Reversed historically deteriorating net revenue per gram in 2012 ASP for 2Q13 increased for third consecutive quarter 7 2013 2012 5% Net Revenue per Gram * Net price per gram is calculated by deducting estimated fees, d
Slide 8: First Quarter Financial Highlights
FIRST QUARTER FINANCIAL HIGHLIGHTS ($ in millions, except per share ) 1Q13 1Q12 Growth Total Revenues $17.9 $15.5 16% Net Feraheme US Product Revenues $15.6 $13.1* 19% Feraheme Gross Margin % of product sales $12.8 82% $10.5* 77% 23% R&D Expenses $5.4 $12.5 (57%) SG&A Expenses $14.0 $13.2 5% Net Los
Slide 9: 2013 Financial Outlook
2013 FINANCIAL OUTLOOK 9 Expenses (in millions) Total Revenues of $73 - $77 million $63 – $67 million in U.S. Feraheme net sales Operating expenses of $78– $82 million (excluding COGS) COGS: 14%-18% of global Feraheme sales End 2013 with $206 – $211 million of cash and investments, not including the
Slide 10: Feraheme Performance
FERAHEME PERFORMANCE Greg Madison, Chief Commercial Officer
Slide 11: IV Iron Non-Dialysis Market Dynamics
IV IRON NON-DIALYSIS MARKET DYNAMICS 11 IV iron market flat year over year Shifting practice patterns beginning to emerge Hospitals acquiring hem/onc practices HOPPS changes; Feraheme continues to be fully reimbursed Source: IMS Health Data.
Slide 12: 1Q13 – Record Feraheme Non-Dialysis Provider Demand
1Q13 – RECORD FERAHEME NON-DIALYSIS PROVIDER DEMAND 12 Source: IMS Health Data. 11% Grams 1Q13 Results 11% increase in Feraheme provider demand; 110 evolution index 24% growth in hospital 14% share of non-dialysis IV iron market 26% of hem/onc segment; e.i. 104 9% of hospital segment; e.i. 123 40% o
Slide 13: Strategies Driving Double-Digit Volume Growth
Targeting accounts, with differentiated strategy, message and tactics Tracking progress against growth & volume goals across all segments STRATEGIES DRIVING DOUBLE-DIGIT VOLUME GROWTH 13
Slide 14: U.S. Broad IDA IV Iron Market Opportunity Today
U.S. BROAD IDA IV IRON MARKET OPPORTUNITY TODAY Current Feraheme Opportunity Sources: U.S. Census; U.S. Renal Data System, USRDS 2010 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States, National Institutes of Health, National Institute of Diabetes an
Slide 15: IV Iron Referrals - Today
IV IRON REFERRALS - TODAY 15 Patients with Iron deficiency anemia IV iron Fail or intolerant Oral Iron IBD, Celiac, bariatric surgery Gastroenterology Abnormal Uterine Bleeding OB/GYN Crohn’s, arthritis Rheumatology CHF Cardiology Non - dialysis CKD Nephrology IV Iron Administration Hematologist /On
Slide 16: IV Iron Referrals - Tomorrow
IV IRON REFERRALS - 16 Patients with Iron deficiency anemia Fail or intolerant Oral Iron IV iron TOMORROW IBD, Celiac, bariatric surgery Gastroenterology Abnormal Uterine Bleeding OB/GYN Crohn’s , arthritis Rheumatology CHF Cardiology Non - dialysis CKD Nephrology INCREASE THE RATE OF ORAL IRON FAIL
Slide 17: Gastroenterology – A Prime Opportunity Upon Approval
GASTROENTEROLOGY – A PRIME OPPORTUNITY UPON APPROVAL 17 Causes of IDA Chronic GI disorders Inflammatory bowel disease >150,000 with IDA Bleeds of unknown origin Malabsorption disorders Celiac disease Bariatric surgery patients >150,000 with IDA Cannot tolerate or absorb oral iron Chronically iron de
Slide 18: GI Launch Planning
GI LAUNCH PLANNING Developing launch strategies and tactics Market research Advisory boards Meet with key opinion leaders in the treatment of IBD and bariatric surgeons who are thought leaders in IDA Meet with advocacy groups to understand the community Develop reimbursement support documentation Ed
Slide 19: Building Disease State Awareness – Iron Matters
BUILDING DISEASE STATE AWARENESS – IRON MATTERS 19
Slide 20: The Unmet Need That Exists with IDA
“I refused to continue to feel like the walking dead so I took matters into my own hands. Now that my iron deficiency has been corrected, I am a different person. I am more active with my children and am not dreading the next decade of my life – I’m embracing it.” THE UNMET NEED THAT EXISTS WITH IDA
Slide 21: Expansion Opportunities
| EXPANSION OPPORTUNITIES PD
Slide 22: Business Development Target Categories
BUSINESS DEVELOPMENT TARGET CATEGORIES Bulls-Eye Hem/onc or hospital company or product $10-60 MM / yr. revenues IP runway Immediately accretive Opportunity for growth Strategic Opportunities aligned with Feraheme growth strategy (e.g. GI, Rheum) Financial Similarly sized (or smaller) specialty comp
Slide 23: Building Off 1Q Success in 2013
BUILDING OFF 1Q SUCCESS IN 2013 Achieve full year double-digit growth of Feraheme in CKD patient population Continue to realize increasing net revenue per gram of Feraheme sNDA Formal acceptance by FDA – 1Q13 Planned approval & launch – 4Q13 Pre-launch activities for potential broader IDA indication
Slide 24: AMAG Pharmaceuticals: Well Positioned for Growth in 2013 and Beyond
AMAG PHARMACEUTICALS Well positioned for growth in 2013 and beyond